<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03555942</url>
  </required_header>
  <id_info>
    <org_study_id>FSD-COR-2017-01</org_study_id>
    <nct_id>NCT03555942</nct_id>
  </id_info>
  <brief_title>Luteal Phase-start Ovarian Stimulation With Corifollitropin Alfa</brief_title>
  <official_title>Follicular or Luteal Start Ovarian Stimulation With Corifollitropin Alfa. A Prospective Equivalence Study With Repeated Ovarian Stimulation in Oocyte Donors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Universitari Dexeus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Universitari Dexeus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effect of random-start of ovarian stimulation initiated in the early
      follicular or luteal phase on the pharmacokinetics and follicular dynamics and embryo
      euploidy rates in oocyte donors treated with identical ovarian stimulation protocols with
      corifollitropin alfa and GnRH antagonist pituitary downregulation
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The scope of the current prospective trial is to investigate whether Luteal Stimulation (LS)
      results in equivalent euploid embryos with Follicular Stimulation (FS) in young reproductive
      age women. The use of the &quot;oocyte donor model&quot; allows extrapolation of the results and
      application of LS routinely not only in healthy women undergoing fertility preservation but
      also in all patients irrespective of the menstrual date. This may indeed allow widespread
      introduction of LS in IVF programs which may result in proper scheduling of ovarian
      stimulation which is a major issue in everyday clinical practice.

      Given that the pharmacokinetics and follicular dynamics of 150μg corifollitropin alfa for
      luteal stimulation has never been evaluated, the current study of luteal stimulation with
      corifollitropin alfa could be very interesting for several reasons:

        1. Potentially immediate synchronization of oocyte donors with recipients aiming to fresh
           oocyte donation.

        2. Fertility preservation patients for medical, oncological and non-medical indication

        3. Any situation in which endometrial receptivity is not pursued.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 8, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Overall, 44 oocyte donors women will be asked to participate in a trial in which they will undergo 2 consecutive ovarian stimulation protocols within a period of 6 months with 150μg corifollitropin alfa followed by 200 IU rFSH in a fixed GnRH antagonist protocol starting in the early follicular, and luteal menstrual cycle phase</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean number of euploid embryos</measure>
    <time_frame>15-45 days following oocyte retrieval procedure</time_frame>
    <description>Number of euploid embryos between oocytes received from follicular phase or luteal phase initiation of ovarian stimulation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of oocytes</measure>
    <time_frame>9 -20 days from initiation of ovarian stimulation</time_frame>
    <description>The outcome will be evaluated on the day of oocyte retrieval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of MIIs</measure>
    <time_frame>9 -20 days from initiation of ovarian stimulation</time_frame>
    <description>The outcome will be evaluated on the day of oocyte retrieval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total additional dose of rFSH (IU)</measure>
    <time_frame>9 -20 days from initiation of ovarian stimulation</time_frame>
    <description>Addition total units of FSH following corifollitropin alfa.The outcome will be evaluated on the day of final oocyte maturation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of ovarian stimulation</measure>
    <time_frame>9 -20 days from initiation of ovarian stimulation</time_frame>
    <description>Total days of ovarian stimulation .The outcome will be evaluated on the day of final oocyte maturation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endocrine profile at specific intervals</measure>
    <time_frame>Stimulation day 1, day 6, day 8, and Day of final oocyte maturation (actual day may vary between 9-15)</time_frame>
    <description>Estradiol, LH, FSH, Progesterone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy rates following transfer of embryos generated from oocytes from follicular phase vs. luteal phase stimulation</measure>
    <time_frame>5-8 weeks after embryo transfer procedure</time_frame>
    <description>Clinical pregnancy rates , presence of intrauterine gestational sac with an embryonic pole demonstrating cardiac activity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Early follicular phase protocol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>On day 2 or 3 of the menstrual cycle, following baseline blood sampling, a single SC injection of 150 ìg corifollitropin alfa will be administered (Stimulation Day 1). Starting on Stimulation Day 6, the subject will receive a daily SC injection of 0.25 mg ganirelix up to and including the day of GnRH agonist triggering administration to prevent premature LH surges. From Stimulation Day 8 onwards treatment is continued with a daily SC dose of rFSH (200IU/day) up to the day of GnRHa administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Luteal phase protocol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following baseline blood sampling on cycle day 2 of 3 of the menstrual cycle, patients will be followed up with blood and ultrasound from cycle day 10 onwards till the detection of serum LH peak. LH peak will be defined as an increase in serum LH above 20IU/LH. Five (5) days after the LH peak a single SC injection of 150 ìg corifollitropin alfa will be administered (Stimulation Day 1). Starting on Stimulation Day 6, the subject will receive a daily SC injection of 0.25 mg ganirelix up to and including the day of GnRH agonist triggering administration to prevent premature LH surges. From Stimulation Day 8 onwards treatment is continued with a daily SC dose of rFSH (200IU/day) up to the day of GnRHa administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Follicular phase corifollitropin alfa</intervention_name>
    <description>GnRH antagonist protocol with corifollitropin alfa initiated in the follicular phase (day 2 or 3 of the menstrual cycle)</description>
    <arm_group_label>Early follicular phase protocol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Luteal phase corifollitropin alfa</intervention_name>
    <description>GnRH antagonist protocol with corifollitropin alfa initiated in the luteal phase (5 days after an LH peak)</description>
    <arm_group_label>Luteal phase protocol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy eligible oocyte donors

          2. Age 18-34 years

          3. AFC &gt;12 and AMH&gt;1.5 ng/ml

          4. BMI 19-28kg/m2

          5. Body weight &gt;60kg

          6. Both ovaries present

          7. Willing to participate in the study

          8. Willing to use non-hormonal contraception or not needing contraception Recipients will
             be eligible only if their partners' sperm which will be used for ICSI will be normal.
             Couples will be excluded in case of moderate to severe oligoasthenospermia.

        Exclusion Criteria:

          1. Endometriosis

          2. AFC&gt;20

          3. PCOS

          4. Low ovarian reserve

          5. Endocrine abnormalities

          6. Hormonal contraception

          7. Contraindication of hormonal treatment

          8. History of Ovarian Hyperstimulation Syndrome or hyper-response (&gt; 30 follicles .

        11mm)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Consultorio Dexeus</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignacio Rodriguez, Msc</last_name>
      <phone>0034932274700</phone>
      <phone_ext>22029</phone_ext>
      <email>nacrod@dexeus.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Departamento de Ginecología Obstetricia y Reproducción. Hospital Universitari Dexeus</name>
      <address>
        <city>Barcelona</city>
        <zip>08037</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignacio Rodríguez, BsC</last_name>
      <phone>0034932274700</phone>
      <phone_ext>22029</phone_ext>
      <email>nacrod@dexeus.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>May 8, 2018</study_first_submitted>
  <study_first_submitted_qc>June 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2018</study_first_posted>
  <last_update_submitted>February 10, 2020</last_update_submitted>
  <last_update_submitted_qc>February 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institut Universitari Dexeus</investigator_affiliation>
    <investigator_full_name>Nikolaos Polyzos</investigator_full_name>
    <investigator_title>Clinical and Scientific Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

